Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Mississippi › Hattiesburg
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Hattiesburg, MS keessatti
Qorannoo 8 Kansara Qara'a Non-Small Cell f Hattiesburg fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 3
- Hattiesburg Clinic /ID# 248033, Hattiesburg
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 2
- Local Institution - 0180, Hattiesburg
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Namoota walitti qabaa jiraSadarkaa 3
- Hattiesburg Clinic Hematology/Oncology ( Site 0104), Hattiesburg
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Hattiesburg Clinic Hematology/Oncology, Hattiesburg
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Hattiesburg
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Namoota walitti qabaa jiraSadarkaa 3
- Hattiesburg Clinic Hematology/Oncology, Hattiesburg
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Study Site, Hattiesburg
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Hattiesburg
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
Qorannoo biroo Hattiesburg keessatti
- Dhukkubaa AlzheimerQorannoo 4
- Saree (Gosoota Hunda)Qorannoo 4
- Kansarii ColorectalQorannoo 4
- Lymphoma FollicularQorannoo 3
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.